Publishing News, newswire

Publishing News & Press Release Distribution Services

Submit Press Release | About Us

Home | Publishing News | News Releases | Press Release Distribution | Free Trade Magazines
Unlimited Press Release Distribution
Press release distribution service

Media List
AllThings Digital
Digital Book World
Editor & Publisher
Good E-Reader
Folio
GalleyCat
O'Reilly Media
Publishing News Brazil
Publishing Trendsetter
Publishers Weekly
Salon
Self Publishing
The Digital Reader
TeleRead

Free Publications


Yes! Please subscribe me!

 
Enter email address above.

Publishing News and Press Releases

Liquid Biopsy in Breast Cancer Market Worth $411.1 Million by 2022 - Exclusive Report by MarketsandMarkets™

(Publishing-NewsWire.com, October 06, 2021 ) According to a new market research report "Liquid Biopsy in Breast Cancer Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022", published by MarketsandMarkets™, the market is expected to reach USD 411.1 million by 2022 from USD 145.4 million in 2017, at a CAGR of 23.1%.

Browse 15 market data Tables and 11 Figures spread through 82 Pages and in-depth TOC on "Breast Cancer Liquid Biopsy Market"

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=150106081

The key factors driving the growth of this market include increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

By circulating biomarkers, cell-free DNA (cfDNA) is expected to account for the largest market share in 2017

Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. In 2017, the cfDNA segment is expected to account for the largest share of the Liquid Biopsy in Breast Cancer Market. The ability of cfDNA for easy and early assessment of patient prognosis and occurrence in other body fluids along with blood is driving the growth of the cfDNA segment in the Breast Cancer Liquid Biopsy Market.

By end user, the reference laboratories segment accounted for the largest market share in 2017

Based on end user, the Liquid Biopsy in Breast Cancer Market is segmented into reference laboratories, hospitals and physician laboratories, and other end users (research institutes, public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories owing to their well-equipped set up for genetic testing.

North America dominated the market in 2017

North America accounted for the largest share of the Breast Cancer Liquid Biopsy Market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of breast cancer in the US and Canada, technological advancements in breast cancer liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=150106081

The key players in the global Liquid Biopsy in Breast Cancer Market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/breast-cancer-liquid-biopsy.asp

MarketsandMarkets™

Mr. Aashish Mehra

1-888-600-6441

raviraj.tak@marketsandmarkets.com

Source: EmailWire.Com

Publishing News by Sector
  • Management
  • Online Publishing
  • People
  • Manufacturing
  • Production
  • Syndication
  • Technology
  • Publihing Resource Center
    We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including:

    Governing
    Point of Beginning
    Overall Labor Effectiveness (OLE) Achieving a Highly Effective Workforce

    No credit cards, coupons, or promo codes required. Try it today!

    Press release service

    Publishing-Newswire.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

    For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com.


    GroupWeb Media Network
    AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
    | InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |

    Publishing-Newswire.Com - Newswire and Press Release service of GroupWeb Media LLC